However, alongside beneficial effects (87, 92–97), clearly supporting the use of Tα1 in COVID-19 via multiple immunity-enhancing and anti-inflammatory protective mechanisms (95), no effects (98–101) or poor clinical outcomes (102) were also observed in COVID-19 patients treated with Tα1, these being inconsistent findings to which the heterogeneity of the disease, including the gender (87, 98, 103), could contribute. The gene discussed is TAAR1; the disease is COVID-19.